Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR

Core Viewpoint - A class action lawsuit has been filed against Nektar Therapeutics and certain officers for alleged violations of federal securities laws during the Class Period from February 26, 2025, to December 15, 2025 [1] Company Overview - Nektar Therapeutics is a biopharmaceutical company focused on developing therapies that modulate the immune system for treating autoimmune disorders [1] - The lead product candidate is rezpegaldesleukin (REZPEG or NKTR-358), aimed at treating alopecia areata [1] Clinical Trial Details - In March 2024, Nektar initiated the Phase 2b REZOLVE-AA trial to evaluate rezpegaldesleukin in 94 patients with severe-to-very severe alopecia areata [1] - The trial's enrollment criteria included specific diagnostic and treatment history requirements [1] - In February 2025, Nektar announced the completion of target enrollment for the REZOLVE-AA trial [1] Allegations in the Lawsuit - The Complaint alleges that during the Class Period, Nektar's executives made materially false and misleading statements regarding the company's business and compliance policies [1] - Specific allegations include failure to disclose that enrollment in the REZOLVE-AA trial did not follow applicable standards, which could negatively impact trial results [1] - The integrity and prospects of the REZOLVE-AA trial were allegedly overstated, leading to misleading public statements [1] Impact of Trial Results - On December 16, 2025, Nektar announced that the REZOLVE-AA trial failed to reach statistical significance, attributed to the inclusion of ineligible patients [1] - Following this announcement, Nektar's stock price fell by $4.14 per share, or 7.77%, closing at $49.16 per share [1]